Which Patients in the FLS Should Be Prioritised for a DXA Scan Within 12 Weeks?
Abstract
1. Introduction
2. Aim
3. Method
4. Results
Needing Treatment Against Osteoporosis? | |||||||
---|---|---|---|---|---|---|---|
No | Yes | Total Number in Each Row | p-Value | ||||
Count | N% | Count | N% | N = 6974 | |||
Gender | Female | 1037 | 19% | 4395 | 81% | 5432 | <0.001 |
Male | 592 | 39% | 909 | 61% | 1501 | ||
Age group | 50–69 | 1247 | 36% | 2308 | 64% | 3555 | <0.001 |
70–79 | 288 | 15% | 1835 | 85% | 2123 | ||
80 and older | 94 | 8% | 1164 | 92% | 1258 |
5. Discussion
5.1. FLS
5.2. The Included Fractures
5.3. Medical Conditions as Risk Factors
5.4. Lifestyle and Ageing Risk Factors
5.5. Clinical Relevance
6. Limitations
7. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Cosman, F.; Lewiecki, E.M.; Eastell, R.; Ebeling, P.R.; De Beur, S.J.; Langdahl, B.; Rhee, Y.; Fuleihan, G.E.; Kiel, D.P.; Schousboe, J.T.; et al. Goal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 2024. J. Bone Min. Res. 2024, 39, 1393–1405. [Google Scholar] [CrossRef]
- Kanis, J.A.; Norton, N.; Harvey, N.C.; Jacobson, T.; Johansson, H.; Lorentzon, M.; McCloskey, E.V.; Willers, C.; Borgstrom, F. SCOPE 2021: A new scorecard for osteoporosis in Europe. Arch. Osteoporos. 2021, 16, 82. [Google Scholar] [CrossRef] [PubMed]
- Akesson, K.; Marsh, D.; Mitchell, P.J.; McLellan, A.R.; Stenmark, J.; Pierroz, D.D.; Kyer, C.; Cooper, C. Capture the Fracture: A Best Practice Framework and global campaign to break the fragility fracture cycle. Osteoporos. Int. 2013, 24, 2135–2152. [Google Scholar] [CrossRef]
- Borgstrom, F.; Lorentzon, M.; Johansson, H.; Harvey, N.C.; McCloskey, E.; Willems, D.; Knutsson, D. Cost-effectiveness intervention thresholds for romosozumab and teriparatide in the treatment of osteoporosis in the UK. Osteoporos. Int. 2024, 35, 2183–2193. [Google Scholar] [CrossRef] [PubMed]
- Leslie, W.D.; Schousboe, J.T.; Morin, S.N.; Martineau, P.; Lix, L.M.; Johansson, H.; McCloskey, E.V.; Harvey, N.C.; Kanis, J.A. Fracture risk following high-trauma versus low-trauma fracture: A registry-based cohort study. Osteoporos. Int. 2020, 31, 1059–1067. [Google Scholar] [CrossRef]
- Skjodt, M.K.; Nicolaes, J.; Smith, C.D.; Olsen, K.R.; Cooper, C.; Libanati, C.; Abrahamsen, B. Fracture Risk in Men and Women with Vertebral Fractures Identified Opportunistically on Routine Computed Tomography Scans and Not Treated for Osteoporosis: An Observational Cohort Study. J. Bone Miner. Res. Plus 2023, 7, e10736. [Google Scholar] [CrossRef]
- Borgstrom, F.; Karlsson, L.; Ortsater, G.; Norton, N.; Halbout, P.; Cooper, C.; Lorentzon, M.; McCloskey, E.V.; Harvey, N.C.; Javaid, M.K.; et al. Fragility fractures in Europe: Burden, management and opportunities. Arch. Osteoporos. 2020, 15, 59. [Google Scholar] [CrossRef]
- Hernlund, E.; Svedbom, A.; Ivergard, M.; Compston, J.; Cooper, C.; Stenmark, J.; McCloskey, E.V.; Jonsson, B.; Kanis, J.A. Osteoporosis in the European Union: Medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch. Osteoporos. 2013, 8, 136. [Google Scholar] [CrossRef]
- Weaver, C.M.; Gordon, C.M.; Janz, K.F.; Kalkwarf, H.J.; Lappe, J.M.; Lewis, R.; O’Karma, M.; Wallace, T.C.; Zemel, B.S. The National Osteoporosis Foundation’s position statement on peak bone mass development and lifestyle factors: A systematic review and implementation recommendations. Osteoporos. Int. 2016, 27, 1281–1386. [Google Scholar] [CrossRef] [PubMed]
- Ishimi, Y. Osteoporosis and Lifestyle. J. Nutr. Sci. Vitaminol. 2015, 61, S139–S141. [Google Scholar] [CrossRef]
- Abdolalipour, S.; Mirghafourvand, M.; Ghassab-Abdollahi, N.; Farshbaf-Khalili, A. Health-promoting lifestyle and quality of life in affected and unaffected menopausal women by primary osteoporosis. J. Educ. Health Promot. 2021, 10, 45. [Google Scholar] [CrossRef]
- Vestergaard, P.; Rejnmark, L.; Mosekilde, L. Methotrexate, azathioprine, cyclosporine, and risk of fracture. Calcif. Tissue Int. 2006, 79, 69–75. [Google Scholar] [CrossRef]
- Subarajan, P.; Arceo-Mendoza, R.M.; Camacho, P.M. Postmenopausal Osteoporosis: A Review of Latest Guidelines. Endocrinol. Metab. Clin. N. Am. 2024, 53, 497–512. [Google Scholar] [CrossRef] [PubMed]
- Lems, W.F. Is Fragility Fracture a Strong Risk Factor for a Cardiovascular Event in Rheumatoid Arthritis? The Challenge of Dealing with Multiple Comorbidities. J. Rheumatol. 2017, 44, 545–546. [Google Scholar] [CrossRef] [PubMed]
- Almeida, O.P.; Page, A.; Sanfilippo, F.M.; Etherton-Beer, C. Prospective Association Between the Dispensing of Antidepressants and of Medications to Treat Osteoporosis in Older Age. Am. J. Geriatr. Psychiatry 2024, 32, 349–357. [Google Scholar] [CrossRef] [PubMed]
- Akesson, K.E.; McGuigan, F.E.A. Closing the Osteoporosis Care Gap. Curr. Osteoporos. Rep. 2021, 19, 58–65. [Google Scholar] [CrossRef]
- Mackey, D.C.; Lui, L.Y.; Cawthon, P.M.; Bauer, D.C.; Nevitt, M.C.; Cauley, J.A.; Hillier, T.A.; Lewis, C.E.; Barrett-Connor, E.; Cummings, S.R.; et al. High-trauma fractures and low bone mineral density in older women and men. JAMA 2007, 298, 2381–2388. [Google Scholar] [CrossRef]
- Toth, E.; Banefelt, J.; Akesson, K.; Spangeus, A.; Ortsater, G.; Libanati, C. History of Previous Fracture and Imminent Fracture Risk in Swedish Women Aged 55 to 90 Years Presenting with a Fragility Fracture. J. Bone Miner. Res. 2020, 35, 861–868. [Google Scholar] [CrossRef] [PubMed]
- Javaid, M.K.; Kyer, C.; Mitchell, P.J.; Chana, J.; Moss, C.; Edwards, M.H.; McLellan, A.R.; Stenmark, J.; Pierroz, D.D.; Schneider, M.C.; et al. Effective secondary fracture prevention: Implementation of a global benchmarking of clinical quality using the IOF Capture the Fracture(R) Best Practice Framework tool. Osteoporos. Int. 2015, 26, 2573–2578. [Google Scholar] [CrossRef]
- Andreasen, C.; Dahl, C.; Frihagen, F.; Borgen, T.T.; Basso, T.; Gjertsen, J.E.; Figved, W.; Wisloff, T.; Hagen, G.; Apalset, E.M.; et al. Fracture liaison service (FLS) is associated with lower subsequent fragility fracture risk and mortality: NoFRACT (the Norwegian capture the fracture initiative). Osteoporos. Int. 2025, 36, 501–512. [Google Scholar] [CrossRef]
- McLellan, A.R.; Wolowacz, S.E.; Zimovetz, E.A.; Beard, S.M.; Lock, S.; McCrink, L.; Adekunle, F.; Roberts, D. Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: A cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos. Int. 2011, 22, 2083–2398. [Google Scholar] [CrossRef]
- Chesser, T.J.S.; Javaid, M.K.; Mohsin, Z.; Pari, C.; Belluati, A.; Contini, A.; Caiaffa, V.; Chana-Rodriguez, F.; Gomez-Vallejo, J.; Sanchez-Perez, C.; et al. Overview of fracture liaison services in the UK and Europe: Standards, model of care, funding, and challenges. OTA Int. 2022, 5 (Suppl. S3), e198. [Google Scholar] [CrossRef]
- Dell, R. Fracture prevention in Kaiser Permanente Southern California. Osteoporos. Int. 2011, 22 (Suppl. S3), 457–460. [Google Scholar] [CrossRef] [PubMed]
- Lv, H.; Nie, Y.; Wang, X.; Li, W.; Wang, Y.; Li, Z.; Zhang, X.; Chen, W. Epidemiological characteristics of fractures of spine, hip, proximal humerus and forearm during the haze epidemic period. Injury 2022, 53, 3139–3148. [Google Scholar] [CrossRef]
- Kanis, J.A.; Johansson, H.; McCloskey, E.V.; Liu, E.; Akesson, K.E.; Anderson, F.A.; Azagra, R.; Bager, C.L.; Beaudart, C.; Bischoff-Ferrari, H.A.; et al. Previous fracture and subsequent fracture risk: A meta-analysis to update FRAX. Osteoporos. Int. 2023, 34, 2027–2045. [Google Scholar] [CrossRef]
- Johansen, A.; Sahota, O.; Dockery, F.; Black, A.J.; MacLullich, A.M.J.; Javaid, M.K.; Ahern, E.; Gregson, C.L. Call to action: A five nations consensus on the use of intravenous zoledronate after hip fracture. Age Ageing 2023, 52, afad172. [Google Scholar] [CrossRef]
- NICE. Osteoporosis: Assessing the Risk of Fragility Fracture. In Clinical Guideline; National Institute for Health and Care Excellence (NICE): London, UK, 2017. [Google Scholar]
- Haque, A.; Singh, H.P. Mortality following combined fractures of the hip and proximal humerus. World J. Orthop. 2020, 11, 426–430. [Google Scholar] [CrossRef]
- Curtin, P.B.; Hall, R.R., 3rd; Molla, V.G.; Lansbury, J.N.; O’Connor, E.P.; Aaron, D.L. Morbidity and mortality of fragility proximal humerus fractures: A retrospective cohort study of patients presenting to a level one trauma center. J. Shoulder Elb. Surg. 2022, 31, 2116–2120. [Google Scholar] [CrossRef] [PubMed]
- Frihagen, F.; Djuv, A.; Nordbø, J.V.; Solberg, L.B. Treatment Guide for Fragility Fractures in Norway (Behandlingsveileder ved Lavenergibrudd). 2022. Available online: https://www.legeforeningen.no/foreningsledd/fagmed/norsk-ortopedisk-forening/faggrupper/faggruppe-for-osteoporose-og-benhelse/behandlingsveileder-ved-lavenergibrudd/ (accessed on 21 May 2024).
- Kanis, J.A.; Johnell, O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos. Int. 2005, 16, 229–238. [Google Scholar] [CrossRef]
- Javaid, M.K.; Sami, A.; Lems, W.; Mitchell, P.; Thomas, T.; Singer, A.; Speerin, R.; Fujita, M.; Pierroz, D.D.; Akesson, K.; et al. A patient-level key performance indicator set to measure the effectiveness of fracture liaison services and guide quality improvement: A position paper of the IOF Capture the Fracture Working Group, National Osteoporosis Foundation and Fragility Fracture Network. Osteoporos. Int. 2020, 31, 1193–1204. [Google Scholar] [CrossRef] [PubMed]
- Montoya-Garcia, M.J.; Carbonell-Abella, C.; Cancio-Trujillo, J.M.; Moro-Alvarez, M.J.; Mora-Fernandez, J.; Izquierdo-Avino, R.; Nogues, X.; Mesa-Ramos, M.; Segundo-Mozo, R.M.S.; Calero-Munoz, E.; et al. Spanish National Registry of Major Osteoporotic Fractures (REFRA) seen at Fracture Liaison Services (FLS): Objectives and quality standards. Arch. Osteoporos. 2022, 17, 138. [Google Scholar] [CrossRef] [PubMed]
- Djuv, A.; Harboe, K.; Nysted, H.; Kirkhus, T.K.; Horpestad, O.; Birkeland, F.H.; Mehl, B.W.; Johnsen, E.; Paulsen, A. Improving the quality of the fracture liaison service through the implementation of a structured health record. BMJ Open Qual. 2023, 12 (Suppl. S2), e002275. [Google Scholar] [CrossRef] [PubMed]
- Jones, C.H.; Dolsten, M. Author Correction: Healthcare on the brink: Navigating the challenges of an aging society in the United States. npj Aging 2024, 10, 25. [Google Scholar] [CrossRef] [PubMed]
- Leal, J.; Gray, A.M.; Hawley, S.; Prieto-Alhambra, D.; Delmestri, A.; Arden, N.K.; Cooper, C.; Javaid, M.K.; Judge, A.; The REFReSH Study Group. Cost-Effectiveness of Orthogeriatric and Fracture Liaison Service Models of Care for Hip Fracture Patients: A Population-Based Study. J. Bone Miner. Res. 2017, 32, 203–211. [Google Scholar] [CrossRef]
- Leslie, W.D.; Majumdar, S.R.; Lix, L.M.; Johansson, H.; Oden, A.; McCloskey, E.; Kanis, J.A. High fracture probability with FRAX usually indicates densitometric osteoporosis: Implications for clinical practice. Osteoporos. Int. 2012, 23, 391–397. [Google Scholar] [CrossRef]
- Kanis, J.A.; McCloskey, E.; Johansson, H.; Oden, A.; Leslie, W.D. FRAX((R)) with and without bone mineral density. Calcif. Tissue Int. 2012, 90, 1–13. [Google Scholar] [CrossRef]
- Lems, W.F.; Paccou, J.; Zhang, J.; Fuggle, N.R.; Chandran, M.; Harvey, N.C.; Cooper, C.; Javaid, K.; Ferrari, S.; Akesson, K.E.G. International Osteoporosis Foundation Fracture Working, Vertebral fracture: Epidemiology, impact and use of DXA vertebral fracture assessment in fracture liaison services. Osteoporos. Int. 2021, 32, 399–411. [Google Scholar] [CrossRef]
- Kannus, P.; Palvanen, M.; Niemi, S.; Parkkari, J.; Jarvinen, M. Epidemiology of osteoporotic pelvic fractures in elderly people in Finland: Sharp increase in 1970–1997 and alarming projections for the new millennium. Osteoporos. Int. 2000, 11, 443–448. [Google Scholar] [CrossRef]
- Pisani, P.; Renna, M.D.; Conversano, F.; Casciaro, E.; Di Paola, M.; Quarta, E.; Muratore, M.; Casciaro, S. Major osteoporotic fragility fractures: Risk factor updates and societal impact. World J. Orthop. 2016, 7, 171–181. [Google Scholar] [CrossRef]
- Chandran, M.; Akesson, K.E.; Javaid, M.K.; Harvey, N.; Blank, R.D.; Brandi, M.L.; Chevalley, T.; Cinelli, P.; Cooper, C.; Lems, W.; et al. Impact of osteoporosis and osteoporosis medications on fracture healing: A narrative review. Osteoporos. Int. 2024, 35, 1337–1358. [Google Scholar] [CrossRef] [PubMed]
- Tang, Y.; Hong, W.; Xu, X.; Li, M.; Jin, L. Traumatic rib fracture patterns associated with bone mineral density statuses derived from CT images. Front. Endocrinol. 2023, 14, 1304219. [Google Scholar] [CrossRef]
- Reid, I.R.; Bolland, M.J. Calcium and/or Vitamin D Supplementation for the Prevention of Fragility Fractures: Who Needs It? Nutrients 2020, 12, 1011. [Google Scholar] [CrossRef] [PubMed]
- Bendik, I.; Friedel, A.; Roos, F.F.; Weber, P.; Eggersdorfer, M. Vitamin D: A critical and essential micronutrient for human health. Front. Physiol. 2014, 5, 248. [Google Scholar] [CrossRef]
- Wang, C.J.; McCauley, L.K. Osteoporosis and Periodontitis. Curr. Osteoporos. Rep. 2016, 14, 284–291. [Google Scholar] [CrossRef]
- Gupta, N.; Kanwar, N.; Arora, A.; Khatri, K.; Kanwal, A. The interplay of rheumatoid arthritis and osteoporosis: Exploring the pathogenesis and pharmacological approaches. Clin. Rheumatol. 2024, 43, 1421–1433. [Google Scholar] [CrossRef] [PubMed]
- Xu, G.; Guo, Y.; Wang, W.; Yu, W.Q.; Chen, Q.M.; Wang, H. Zoledronic acid improves periodontal health, reduces serum inflammation, and enhances bone metabolism in postmenopausal osteoporosis complicated by periodontitis. Am. J. Transl. Res. 2024, 16, 6519–6527. [Google Scholar] [CrossRef] [PubMed]
- Miyamoto, T. Osteoporosis and Rheumatoid Arthritis: Mechanisms Underlying Osteoclast Differentiation and Activation or Factors Associated with Hip Fractures. J. Clin. Med. 2025, 14, 1138. [Google Scholar] [CrossRef]
- Chen, Y.W.; Ramsook, A.H.; Coxson, H.O.; Bon, J.; Reid, W.D. Prevalence and Risk Factors for Osteoporosis in Individuals with COPD: A Systematic Review and Meta-analysis. Chest 2019, 156, 1092–1110. [Google Scholar] [CrossRef]
- Starup-Linde, J.; Stoy, J.; Grinderslev, P.B.; Langdahl, B.; Harslof, T. Prevalence and risk factors for osteoporosis in type 1 diabetes-results from an observational study. Osteoporos. Int. 2025, 36, 823–831. [Google Scholar] [CrossRef]
- Alarkawi, D.; Tran, T.S.; Chen, W.; March, L.M.; Blyth, F.M.; Blank, R.D.; Bliuc, D.; Center, J.R. Health Perceptions, Multimorbidity, and New Fractures and Mortality Among Patients with a Fracture. JAMA Netw. Open 2024, 7, e248491. [Google Scholar] [CrossRef]
- Gebrelibanos, M.B. The Association Between Alcohol Consumption and Self-Rated Health Among Adult Norwegian Women 2023. Master’s Thesis, UiT The Arctic University of Norway, Tromsø, Norway, 2023. [Google Scholar]
- Devaux, M.; Sassi, F. Social disparities in hazardous alcohol use: Self-report bias may lead to incorrect estimates. Eur. J. Public Health 2016, 26, 129–134. [Google Scholar] [CrossRef] [PubMed]
- Eastell, R.; Rosen, C.J.; Black, D.M.; Cheung, A.M.; Murad, M.H.; Shoback, D. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2019, 104, 1595–1622. [Google Scholar] [CrossRef] [PubMed]
- Clynes, M.A.; Westbury, L.D.; Dennison, E.M.; Kanis, J.A.; Javaid, M.K.; Harvey, N.C.; Fujita, M.; Cooper, C.; Leslie, W.D.; Shuhart, C.R.; et al. Bone densitometry worldwide: A global survey by the ISCD and IOF. Osteoporos. Int. 2020, 31, 1779–1786. [Google Scholar] [CrossRef] [PubMed]
- Australian and New Zealand Fragility Fracture Registry. 2025 ANZFFR Annual Report. 2025. Available online: https://fragilityfracture.co.nz/2025-annual-report/ (accessed on 28 July 2025).
Diseases and Fractures: | Need Treatment Against Osteoporosis | ||||
---|---|---|---|---|---|
No | Yes | ||||
Count | N% | Count | N% | p-Value | |
Rheumatoid arthritis | 52 | 15% | 295 | 85% | <0.001 |
Other systemic arthritis | 55 | 14% | 150 | 86% | 0.008 |
Coeliac disease | 18 | 14% | 105 | 86% | 0.003 |
Spondylarthritis | 25 | 27% | 67 | 73% | 0.234 |
Ulcerative colitis | 12 | 23% | 41 | 77% | 0.518 |
Crohn’s disease | 22 | 27% | 57 | 73% | 0.213 |
Diabetes mellitus I and II | 37 | 11% | 292 | 89% | <0.001 |
Asthma or COPD | 171 | 28% | 447 | 72% | 0.006 |
Hyperthyroidism | 194 | 19% | 853 | 81% | <0.001 |
Ventricular ulcer or GERD | 20 | 14% | 118 | 86% | 0.006 |
Periodontitis or other dental disease | 132 | 16% | 692 | 84% | <0.001 |
Vertebral fracture | 93 | 9% | 917 | 91% | <0.001 |
Wrist fracture | 381 | 27% | 1009 | 73% | 0.002 |
Proximal humerus fracture | 185 | 29% | 456 | 71% | <0.001 |
Ankle fracture | 387 | 45% | 478 | 55% | <0.001 |
Hip fracture | 71 | 11% | 579 | 89% | <0.001 |
Pelvic fracture | 26 | 9% | 268 | 91% | <0.001 |
Costa fracture | 242 | 27% | 670 | 73% | 0.012 |
Lifestyle Risks: | Need Anti-Osteoporotic Treatment? | |||||
---|---|---|---|---|---|---|
No | Yes | |||||
Count | N% | Count | N% | p-Value | ||
Fall from standing or sitting? | No | 414 | 47% | 470 | 53% | <0.001 |
Yes | 969 | 20% | 3774 | 80% | ||
Performing activity for 90 min or more (exercise/walk) a week? | No | 1506 | 24% | 4709 | 76% | <0.001 |
Yes | 123 | 17% | 598 | 83% | ||
Exercising strength or balance for a minimum of 90 min per week? | No | 1362 | 23% | 4436 | 77% | 0.509 |
Yes | 267 | 23% | 871 | 77% | ||
Drinking alcohol | No | 1023 | 21% | 3874 | 79% | <0.001 |
Yes | 606 | 30% | 1433 | 70% | ||
Drinking alcohol ≥6 units per week? | No | 1309 | 24% | 4127 | 76% | <0.001 |
Yes | 74 | 39% | 117 | 61% | ||
Cigarette smoking | No | 711 | 24% | 2302 | 76% | 0.435 |
Yes | 918 | 23% | 3005 | 77% | ||
Adequate vitamin D values (<50 nmol/L)? | No | 111 | 37% | 189 | 63% | <0.001 |
Yes | 955 | 23% | 3243 | 77% | ||
Previous fracture before index fracture? | No | 745 | 29% | 1828 | 71% | <0.001 |
Yes | 611 | 20% | 2443 | 80% | ||
Body mass index (BMI) | Normal | 954 | 19% | 3985 | 81% | <0.001 |
Low | 8 | 6% | 119 | 94% | ||
Obese | 526 | 42% | 728 | 58% |
Included Variables | OR | 95% C.I. for OR | p-Value | |
---|---|---|---|---|
Lower | Upper | |||
Age 80+ | 2.23 | 1.981 | 2.513 | 0.000 |
Female gender | 3.49 | 2.932 | 4.155 | 0.000 |
Vertebral fracture | 3.12 | 2.428 | 4.002 | 0.000 |
Ankle fracture | 0.60 | 0.495 | 0.724 | 0.000 |
Hip fracture | 2.60 | 1.920 | 3.467 | 0.000 |
Pelvic fracture | 3.05 | 1.809 | 5.138 | 0.000 |
Costa fracture | 1.26 | 1.025 | 1.544 | 0.028 |
Previously fracture | 1.41 | 1.225 | 1.629 | 0.000 |
Asthma or COPD | 0.67 | 0.518 | 0.867 | 0.002 |
Low level of vitamin D | 1.43 | 1.115 | 1.846 | 0.005 |
Fall from standing, walking or sitting | 2.76 | 2.319 | 3.288 | 0.000 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nysted, H.; Horpestad, O.; Djuv, A. Which Patients in the FLS Should Be Prioritised for a DXA Scan Within 12 Weeks? J. Clin. Med. 2025, 14, 5619. https://doi.org/10.3390/jcm14165619
Nysted H, Horpestad O, Djuv A. Which Patients in the FLS Should Be Prioritised for a DXA Scan Within 12 Weeks? Journal of Clinical Medicine. 2025; 14(16):5619. https://doi.org/10.3390/jcm14165619
Chicago/Turabian StyleNysted, Hege, Oda Horpestad, and Ane Djuv. 2025. "Which Patients in the FLS Should Be Prioritised for a DXA Scan Within 12 Weeks?" Journal of Clinical Medicine 14, no. 16: 5619. https://doi.org/10.3390/jcm14165619
APA StyleNysted, H., Horpestad, O., & Djuv, A. (2025). Which Patients in the FLS Should Be Prioritised for a DXA Scan Within 12 Weeks? Journal of Clinical Medicine, 14(16), 5619. https://doi.org/10.3390/jcm14165619